Immunologic Basis of Anti-IgE Therapy (Study II: On Patients With Asthma)

• Status: Completed
• Trial end date: 2012-10-17
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to look at measures that will help scientists understand the way Omalizumab, an FDA-approved anti-allergy medication, works.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of California, Davis
• Treatments: Omalizumab

Criteria

Inclusion Criteria:

• Mild or moderate persistent asthma

• Allergic rhinitis

• Atopic dermatitis

Exclusion Criteria:

• Other lung diseases

• Blood clotting disorder

• Pregnant or lactating women